

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1498

(Use as many sheets as necessary)

Sheet 1 of 10

Application Number	10/596,062
Filing Date	May 26, 2006
First Named Inventor	Liu et al.
Art Unit	not yet assigned
Examiner Name	not yet assigned
Attorney Docket Number	22727/04398

[illegible]

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	1 ^d
		Country Code ² *Number ³ *Kind Code ⁵ (if known)	MM-DD-YYYY			
		EP 235,726	09/09/1987	Dattagupta et al.		
		WO 89/11548	11/30/1989	Saiki et al.		
		WO 93/22456	11/11/1993	Sorenson		
		WO 95/11995	05/04/1995	Chee et al.		

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language TransJap/JP is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/596,062
Filing Date	May 26, 2006
First Named Inventor	Liu et al.
Art Unit	not yet assigned
Examiner Name	not yet assigned
Attorney Docket Number	22727/04398

Sheet 2 of 10

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Aigner, S., et al., "CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells," Blood 89: (9) 3385-3395 (May 1, 1997).	
		Bai, XF et al "The heat-stable antigen determines pathogenicity of self-reactive T cells in experimental autoimmune encephalomyelitis" J Clin Invest 105 No 9, 1227-32 May 2000	
		Barany, "Genetic Disease Detection and DNA Amplification Using Cloned Thermostable Ligase," Proc. Natl. Acad. Sci. USA, 88: 189-193 (Jan. 1991).	
		Baron, J. L., et al., "Surface Expression of $\alpha 4$ Integrin by CD4 T Cells is Required for Their Entry into Brain Parenchyma," J Exp Med 177:57-68 (Jan. 1993).	
		Carter and Rodriguez, "Immunosuppressive treatment of Multiple Sclerosis," Mayo Clinic Proc. 64: 664 (1989).	
		Carton, H., et al., "Risks of Multiple Sclerosis in relatives of patients in Flanders, Belgium," J Neurol Neurosurg Psychiatry 62:329-33 (1997).	
		Collins, "Positional Cloning: Let's not call it reverse anymore" Nature Genetics 1: 3-6 (Apr. 1992).	
		De Bruijn, ML, et al "Induction of heat-stable antigen expression by phagocytosis is involved in <i>in vitro</i> activation of unprimed CTL by macrophages" J Immunol 156:2686-92 1996	
		Donis-Keller, et al., "A genetic linkage map of the human genome," Cell 51:319-337 (Oct. 23, 1987).	
		Ebers, G. C., et al., "A population-based study of multiple sclerosis in Twins", N Engl J Med 315, 1638-42 (Dec. 25, 1986).	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CM/

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/596,062
		Filing Date	May 26, 2006
		First Named Inventor	Liu et al.
		Art Unit	not yet assigned
		Examiner Name	not yet assigned
Sheet 3	of 10	Attorney Docket Number	22727/04398

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Ebers, G. C., et al., "A full genome search in multiple sclerosis," Nat Genet 13:472-6 (Aug. 1996).	
		Eckert, et al., "DNA polymerase fidelity and the polymerase chain reaction," PCR Methods and Applications 1:17-24 (1991).	
		Eisenhaber, B, et al. "Sequence properties of GPI-anchored proteins near the omega-site: constraints for the polypeptide binding site of the putative transamidase," Protein	
		(continued from line above) Eng 11 (12) 1155-61 (1998).	
		Englund, P. T., "The Structure and Biosynthesis of Glycosyl Phosphatidylinositol Protein Anchors", Annu Rev Biochem 62:121-38 (1993).	
		Enk, A. H. et al, "Heat-Stable Antigen is an Important Costimulatory Molecule on Epidermal Langerhans' Cells", J Immunol 152:3264-70 (1994).	
		Fischer, GF et al "Signal transduction in myeloid cells via CD24, a new member of phosphoinositol-anchored membrane molecules" J Immun 144:638-641, 01/15/1990	
		Gasparini, et al., "Restriction site generating-polymerase chain reaction (RG-PCR) for the probess detection of hidden genetic variation: application to the study of some	
		(continued from line above) common cystic fibrosis mutations," Mol. Cell Probes 6: 1-7 (1992).	
		Gene Bank Accession: NM_013230, 12/03/2006, 4 pgs.	

Examiner Signature	Date Considered
---------------------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CM/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/596,062
		Filing Date	May 26, 2006
		First Named Inventor	Liu et al.
		Art Unit	not yet assigned
		Examiner Name	not yet assigned
Sheet 4	of 10	Attorney Docket Number	22727/04398

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Gibbs, "Detection of single DNA base differences by competitive oligonucleotide priming," Nucleic Acid Res. 17 (7):2437-2448 (1989).	
		Guatelli, et al, "Isothermal, In Vitro Amplification of Nucleic Acids by a Multienzyme Reaction Modeled After Retroviral Replication" Proc Natl Acad Sci, USA 87:1874-78 (1990)	
		Hahne, M. , et al., "The Heat-stable Antigen Can Alter Very Late Antigen 4-mediated Adhesion", J Exp Med 179:1391-5 (Apr. 1994).	
		Haines, J. L., et al., "A complete genomic screen for multiple sclerosis underscores a role for the major histocompatibility complex", Nat Genet 13:469-71 (Aug. 13, 1996).	
		Haines, J. L. , et al., "Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity", Hum Mol Genet 7 (8): 1229- 34 (1998).	
		Hough, M.R., et al., "Mappig of CD24 and homologous sequences to multiple chromosomal loci" Genomics 22: 154-161 (1994).	
		Hubbe, M. et al., "Heat-Stable Antigen/CD24 on mouse T lymphocytes: evidence for a costimulatory function," Eur J Immunol 24:731-737 (1994).	
		Kellar-Wood, H. F. , et al., "Multiple Sclerosis and the HLA-D region: linkage and association studies," J Neuroimmunol 58:183-90 (1995).	
		Kerem, et al., "Identification of the cystic fibrosis gene: genetic analysis," Science 245:1073-1080, (Sept. 8, 1989).	
		Kuokkanen, S., et al, "A putative vulnerability locus to multiple sclerosis maps to 5p14-p12 in a region syntenic to the murine locus Eae2", Nat Genet 13:477-80 (Aug. 13, 1996)	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CM/

Substitute for form 1449/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Application Number	10/596,062
Filing Date	May 26, 2006
First Named Inventor	Liu et al.
Art Unit	not yet assigned
Examiner Name	not yet assigned
Attorney Docket Number	22727/04398

Sheet 5

of

10

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Kurtzke, J. F. "Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)," <i>Neurology</i> 33:1444-1452 (Nov. 1983).	
		Kurtzke, "Clinical definition for multiple sclerosis treatment trials," <i>Ann. Neurol.</i> 36:S73-S79, (1994).	
		Kwoh, et al., "Transcription-based amplification system and detection of amplified human immunodeficiency virus type 1 with a bead-based sandwich hybridization format", <i>Proc.</i>	
		(continued from line above) <i>Natl. Acad. Sci. USA</i> 86:1173-1177 (Feb. 1989).	
		Landegren, U., et al., "A ligase-mediated gene detection technique," <i>Science</i> 241:1077-1080 (Aug. 26, 1988).	
		Lander, et al., "Strategies for Studying Heterogeneous Genetic Traits in Humans by Using a Linkage Map of Restriction Fragment Length Polymorphisms," <i>Proc. Natl. Acad. Sci.</i>	
		(continued from line above) <i>USA</i> 83:7353-7357 (Oct. 1986).	
		Lander, et al., "Construction of multilocus genetic linkage maps in humans," <i>Proc. Natl. Acad. Sci. USA</i> 84:2363-2367 (Apr. 1987).	
		Lander, et al., "Mapping Mendelian Factors Underlying Quantitative Traits Using RFLP Linkage Maps," <i>Genetics</i> 121:185-199 (Jan. 1989).	
		Lathrop, "Strategies for Multilocus linkage analysis in humans," <i>Proc. Nat. Acad. Sci. USA</i> 81:3443-3446 (Jun. 1984).	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CM/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Application Number	10/596,062
Filing Date	May 26, 2006
First Named Inventor	Liu et al.
Art Unit	not yet assigned
Examiner Name	not yet assigned
Attorney Docket Number	22727/04398

Sheet 6

of

10

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Liu, Y., et al., "Co-stimulation of murine CD4 T cell growth: cooperation between B7 and heat-stable antigen", Eur J Immunol 22:2855-2859 (1992).	
		Liu, Y., et al., "Heat-stable Antigen is a Costimulatory Molecule for CD4 T Cell Growth", J. Exp. Med. 175:437-45 (Feb. 1992).	
		Liu, Y., et al., "Distinct Costimulatory Molecules are Required for the Induction of Effector and Memory Cytotoxic T Lymphocytes," J Exp Med 185 (2): 251- 62 (Jan. 20, 1997).	
		Liu, X., et al., "B7H Costimulates Clonal Expansion of, and Cognate Destruction of Tumor Cells by, CD8+ T Lymphocytes in Vivo," J. Exp. Med. 194 (9):1339-1348 (Nov. 5, 2001).	
		Martin, E. R., et al., "A Test for Linkage and Association in General Pedigrees: The Pedigree Disequilibrium Test," Am J Hum Genet 67:146-54 (2000).	
		Mattila, et al, "Fidelity of DNA synthesis by the Thermococcus litoralis DNA polymerase-an extremely heat stable enzyme with proofreading activity" Nucleic Acids Res 19 (1991)	
		McDonald, et al. "Are magnetic resonance findings predictive of clinical outcome in therapeutic trials in multiple sclerosis? The dilemma of interferon-beta," Ann. Neurol.	
		(continued from line above) 36:14-18 (1994).	
		McDonald, W. I., et al., "Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis," Ann Neurol.	
		(continued from line above) 50:121-7 (2001).	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CM/

Substitute for form 1449/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 7

of

10

Application Number	10/596,062
Filing Date	May 26, 2006
First Named Inventor	Liu et al.
Art Unit	not yet assigned
Examiner Name	not yet assigned
Attorney Docket Number	22727/04398

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		McKusik, V.A., CD24 Antigen; CD24, OMIM Online Mendelian Inheritance in Man, available at: http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=600074 (created 8/4/1994, last	
		(continued from line above) updated 6/14/2006), 3 pgs.	
		Miller, D. H. , et al. "Class II HLA antigens in multiple sclerosis," J Neurol Neurosurg Psychiatry 52:575-7 (1989).	
		Mitchell, "Update on Multiple Sclerosis Therapy", Cont. Clin., Neurol. 77 (1): 231-249 (Jan. 1993).	
		Monaco, et al., "Detection of deletions spanning the Duchenne muscular dystrophy locus using a tightly linked DNA segment," Nature 316:842-845, Aug. 29 1985.	
		Morling, N., et al., "Immunogenetics of multiple sclerosis and optic neuritis: DNA polymorphism of HLA class II genes," Immunogenetics 35:391-4 (1992).	
		Nickerson, D.A., et al., "Automated DNA diagnostics using an ELISA-based oligonucleotide ligation assay," Proc. Natl. Acad. Sci. USA, 87:8923-8927 (Nov. 1990).	
		Noseworthy, J. H. "Progress in determining the causes and treatment of multiple sclerosis," Nature 399 Supp., A40-47 (Jun. 24, 1999).	
		Okamoto, M., et al., "Heterogeneous Expressions of GPI-Anchored Proteins by Granulocytes from Patients with Aplastic Anemia (AA) and Myelodysplastic Syndrome (MDS)," Journal	
		(continued from line above) Blood 100 (11); No. 3508, ABSTRACT ONLY (Nov. 16, 2002).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CM/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/596,062
Filing Date	May 26, 2006
First Named Inventor	Liu et al.
Art Unit	not yet assigned
Examiner Name	not yet assigned
Attorney Docket Number	22727/04398

Sheet 8

of

10

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Olerup, O. et al. "HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation," Tissue Antigens 38:1-15 (1991).	
		Paty, et al., "Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-	
		(continued from line above) controlled trial. UCB MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group," Neurology 43:662-667 (Apr. 1993).	
		Prossner, "Detecting single-base mutations", Tibtech 11: 238-246, (Jun. 1993).	
		Rossiter, et al., "Molecular studies of human genetic disease," FASEB Journal 5:21-27 (Jan. 1991).	
		Saiki, et al., "Analysis of enzymatically amplified B-globin and HLA-Dqa DNA with allele-specific oligonucleotide probes," Nature 324:163-166 (Nov. 13, 1986).	
		Saiki, et al., "Genetic analysis of amplified DNA with immobilized sequence-specific oligonucleotide probes," Proc. Natl. Acad. Sci. USA, 86:6230-6234 (Aug. 1989).	
		Sawcer, S., et al., "A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22", Nat Genet 13,464-8 (Aug. 13, 1996).	
		Schmidt, S, et al, "Association of Polymorphisms in the Apolipoprotein E Region with Susceptibility to and Progression of Multiple Sclerosis," Am J Hum Genet 70:708-17 (2002)	
		Smith, "Linkage scores and corrections in simple two-and three-generation families", Ann. Hum. Genet. 32, 127-150 (1968).	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CM/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/596,062
		Filing Date	May 26, 2006
		First Named Inventor	Liu et al.
		Art Unit	not yet assigned
		Examiner Name	not yet assigned
Sheet 9	of 10	Attorney Docket Number	22727/04398

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Spielman, R. S. et al. "A Sibship Test for Linkage in the presence of association: The Sib Transmission/Disequilibrium Test," Am J Hum Genet 62:450-8 (1998).	
		Tobe, et al., "Single-well genotyping of diallelic sequence variations by a two-color ELISA-based oligonucleotide ligation assay," Nucleic Acids Res. 24 (19): 3728-3732 (1996)	
		Udenfriend, S. et al., "How glycosyl-phosphatidylinositol-anchored membrane proteins are made", Annu Rev Biochem 64:563-91 (1995).	
		Van der Schoot, et al. "Identification of three novel PI-linked proteins on granulocytes." In: Knapp, W.; et al., Leukocyte Typing IV: White Cell Differentiation Antigens, (continued from line above) pp. 887-891. (Oxford Univ. Press, Oxford, 1989).	
		Wainright, "The isolation of disease genes by positional cloning", Med. J. Australia, 159, 170-174 (Aug. 2, 1993).	
		Weiner and Hafler, "Immunotherapy of multiple sclerosis," Ann. Neurol, 23:211-222 (1988).	
		Wu et al, "The ligation amplification reaction (LAR)--amplification of specific DNA sequences using sequential rounds of template-dependent ligation" Genomics 4:560-569 (1989)	
		Wu, Y, et al "CD28-independent Induction of T Helper Cells and Immunoglobulin Class Switches Requires Costimulation by the Heat-stable Antigen" J Exp Med 187 (7):1151-1156	
		(continued from line above) (Apr. 6, 1998)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CM/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/596,062
		Filing Date	May 26, 2006
		First Named Inventor	Liu et al.
		Art Unit	not yet assigned
		Examiner Name	not yet assigned
		Attorney Docket Number	22727/04398
Sheet 10	of 10		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Yamoka, et al., "Tight linkage of creatine kinase (CKMM) to myotonic dystrophy on chromosome 19," Neurology 40:222-226 (Feb. 1990).	
		Zarn, J. A., et al., "The small cell lung cancer antigen cluster-4 and the leukocyte antigen CD24 are allelic isoforms of the same gene (CD24) on chromosome band 6q21,"	
		(continued from line above) Cytogenet Cell Genet 70:119-25 (1995).	
		Zhou Q, et al "Homotypic interaction of the heat-stable antigen is not responsible for its co-stimulatory activity for T cell clonal expansion" Eur J Immunol 27:2524-2528 1997	
		Zhou, Q., et al., "CD24 is a genetic modifier for risk and progressin of multiple sclerosis," PNAS, 100 (25):15041-15046 (Dec. 9, 2003).	
		http://www-frodo.wi.mit.edu/cgi-bin/primer/primer3_www.cgi , 5 pgs. printed 08/25/06	
		International Search Report from PCT/US2004/039391, mailed June 6, 2005.	

Examiner Signature	/Carla Myers/	Date Considered	07/08/2009
---------------------------	---------------	------------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CM/